Germany Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Germany recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Germany recombinant protein therapeutics cdmo market highlights
- The Germany recombinant protein therapeutics cdmo market generated a revenue of USD 1,095.3 million in 2023 and is expected to reach USD 2,892.8 million by 2030.
- The Germany market is expected to grow at a CAGR of 14.9% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 1,095.3 million |
| Market revenue in 2030 | USD 2,892.8 million |
| Growth rate | 14.9% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Germany accounted for 5.2% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 2,892.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.47% in 2023. Horizon Databook has segmented the Germany recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Germany is expected to play a significant role in the recombinant protein therapeutics CDMO market in Europe. The increased requirement for improved product designs and related services in the country is expected to be a key factor driving market growth in the coming years. Advancements in technology and quality clinical resources are some of the key factors expected to propel market growth over the forecast period.
In addition, government initiatives for clinical research activities have accelerated market growth. Moreover, Germany has one of the largest outsourcing markets, with major companies expanding in other European countries. For instance, in July 2023, Chime Biologics established the European Business Center in Germany to extend its CDMO services into the European market.
Moreover, in December 2023, AGC Biologics (AGC), a CDMO, enlarged its facility in Heidelberg, Germany, with the aim of augmenting its capabilities in manufacturing plasmid DNA (DNA) and messenger RNA (mRNA). The microbial manufacturing capabilities encompass the production of therapeutic proteins, DNA plasmids, and secreted proteins.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Germany Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
